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Arrhythmia, Ventricular Noncompaction,
and Mitral Valve Prolapse
A New Overlapping Phenotype*Jeffrey A. Towbin, MDI n this issue of the Journal, 2 elegant papersreport the association of arrhythmia, primarilysinus bradycardia, left ventricular noncompac-
tion (LVNC), and mitral valve prolapse (MVP) (1,2),
demonstrating that the underlying cause is muta-
tion and dysfunction of the hyperpolarization-
activated cyclic nucleotide channel 4 (HCN4), a
major constituent of the pacemaker current (If) in
the sinoatrial node (SAN) (3). The investigatorsSEE PAGES 745 AND 757demonstrate abnormalities in channel function
consistent with the arrhythmia phenotype and spec-
ulate as to the underlying pathogenesis that leads to
LVNC, a heterogeneous myocardial phenotype asso-
ciated with abnormal trabeculation of the LV (4).
Uncertainty, however, belies the question of how
do mutations in this ion channel cause the com-
bined phenotype. To develop a plausible hypo-
thesis, understanding the data reported by these 2
studies, as well as a review of prior studies, is
required.
Schweizer et al. (1) identify HCN4 mutations in 2
unrelated families and an additional unrelated pro-
band with sinus node dysfunction (SND)/brady-
cardia, LVNC, and MVP. Using a candidate gene
approach, they identiﬁed a novel HCN4-G482R loss-*Editorials published in the Journal of the American College of Cardiology
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paper to disclose.of-function mutation, located within the highly
conserved GYG motif of the channel pore domain
that segregated with all affected members in the
4-generation index family (5). The common W4R
variant in the cysteine and glycine-rich protein 3
(CSRP3) gene encoding a Z-disk protein, previously
reported in patients with dilated cardiomyopathy
(DCM) and hypertrophic cardiomyopathy, and healthy
subjects also was identiﬁed (6,7). In addition to
the index family, a second unrelated family and the
unrelated proband were shown to have truncation
(HCN-695X) and missense (HCN-P883R) HCN4 muta-
tions with no mutations identiﬁed in CSRP3. Family
members and probands of all 3 families had severe
SND with or without atrial or ventricular arrhythmias,
syncope, or sudden death and a normal QTc interval.
Noninvasive imaging demonstrated biventricular
hypertrabeculation/LVNC and MVP. Patch-clamp
studies demonstrated no hyperpolarization-activated
inward currents in mutant HCN4-G482R subunits,
consistent with loss of function. Homozygous HCN4-
G482R channels were nonfunctional, and hetero-
meric mutant and wild-type HCN4 channel subunits
had 65% current reduction, consistent with a
dominant-negative mechanism, resulting in If current
reduction in heterozygotes and lower current
densities.
Milano et al. (2) report on 4 families with SND
with or without syncope/cardiac arrest, ventricular
arrhythmias, and atrial arrhythmias, with echocar-
diography demonstrating LVNC with or without
MVP. HCN4 mutations were identiﬁed in all fam-
ilies (Tyr481His in 2 families, Gly482Arg and
Ala414Gly in 1 family each). All mutations affected
conserved residues with 2 mutations (Tyr481His,
Gly482Arg) affecting highly conserved residues
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769within the pore domain of HCN4 and the other
(Ala414Gly) affecting the cytoplasmic S4–S5 linker
of HCN4. Heterologous expression studies with the
Tyr481His and Gly482Arg mutations demonstrated a
large negative shift of the voltage dependence of
activation compared with expression of wild-type
channels, indicating the importance of the pore
region for the voltage dependence of activation. All
mutations resulted in signiﬁcantly lower HCN4
current density.
Together, these studies demonstrate that HCN4
mutations result in loss of function and signiﬁcantly
reduced If current density associated with brady-
cardia, arrhythmias, and LVNC with or without MVP.
Conceptually, these ﬁndings are consistent with the
“ﬁnal common pathway” hypothesis proposed nearly
15 years ago, which suggested that mutations in
genes encoding proteins within the same path-
way (or secondary disturbance of protein function
as a result of binding partner abnormalities, drugs,
and so on) leads to a common phenotype (8). This
hypothesis enabled successful targeted candidate
gene screening for arrhythmias, cardiomyopathies,
and congenital heart disease (CHD), leading to the
current understanding that arrhythmias are caused
by disturbed ion channel function (“ion channelo-
pathies”), hypertrophic cardiomyopathy by disturbed
sarcomere function, DCM by disturbed sarcomere
and cytoskeleton function, and arrhythmogenic right
ventricular cardiomyopathy by disturbed desmo-
some function (9). For LVNC, the picture is less clear;
mutations most commonly occur in sarcomere-
encoding genes, but animal and human data sug-
gest a central role of signaling pathways. In the
cardiomyopathies, ion channel gene mutations also
have been implicated, but the causative mecha-
nism(s) remain unclear.
HCN channels, found in SAN cells and neurons,
are responsible for hyperpolarization-activated cur-
rents, called If in the heart (3,5). The HCN channel
characteristic distinguishing them from other cur-
rents is its unique ion selectivity and gating prop-
erties. The HCN channel family has 4 distinct
members, with HCN4 being the prominent cardiac
form. Native If current, as well as the currents
induced by heterologously expressed HCN channels,
have 4 hallmark properties: 1) channel activation by
membrane hyperpolarization; 2) channel activation
by direct interaction with cAMP; 3) Naþ and Kþ
permeability; and 4) a speciﬁc pharmacological
proﬁle. HCN channels consist of 4 subunits arranged
around the centrally located, pore-forming 4
different homotetramers with distinct biophysical
properties. Each channel subunit consists of: 1)the transmembrane core harboring the gating
machinery and ion-conducting pore; 2) the cytosolic
NH2-terminal domain; and 3) the COOH-terminal
domain with the cyclic nucleotide binding domain
and the peptide connecting the CNBD with the
transmembrane core (the “C-linker”) that confers
modulation by cyclic nucleotides. The If current is
important in the initiation and regulation of the
heartbeat, which is therefore called the “pacemaker
current.” Mutation in the HCN4 gene, located on
chromosome 15q24.1, was ﬁrst reported by Schulze-
Bahr et al. (10) in a patient with SND, atrial ﬁbril-
lation, and chronotropic incompetence. The 1-bp
deletion mutation (HCN4-573X) resulted in a pre-
mature stop codon and a C-terminus lacking the
CNBD domain. In vitro heterologous expression
revealed a dominant-negative loss of cAMP modu-
lation. Several other publications demonstrating
SND with severe bradycardia, with or without atrial
ﬁbrillation or ventricular arrhythmias, have now
been reported. These ﬁndings with HCN4 mutations
would be predicted by the “ﬁnal common pathway”
hypothesis: ion channels cause rhythm disturbance.
However, Schweizer et al. (1) and Milano et al. (2)
report the additional phenotypes of LVNC and MVP
that would not be predicted to result solely from an
ion channel mutation. Schweizer et al. (1) reported
1 family with a CSRP3 variant that is more in line
with the causes of myocardial disease, but this was
not seen in other gene-positive families. So, how
does LVNC occur?
Neither publication presents mechanistic data,
but the investigators speculate on how LVNC and
MVP develop. Schweizer et al. (1) noted that HCN4 is
involved in early embryonic heart development,
helping to form myocardium and the conduction
system. During later development, HCN4 is down-
regulated in the myocardium, with abundant
expression restricted to the SAN and conduction
system. They hypothesize that HCN4 loss of func-
tion interferes with molecular mechanisms required
during cardiac development, resulting in LVNC.
Samsa et al. (11) previously suggested that Notch
pathway disturbance causes LVNC with CHD,
whereas sarcomere, cytoskeletal, and Z-disk muta-
tions cause myocardial disease-only phenotypes.
Based on this, Schweizer et al. (1) suggested
signaling pathway involvement in ventricular wall
maturation and compaction (e.g., Notch, Neuregulin,
Ephrin, or Bone morphogenic protein), could be
involved. Milano et al. (2), on the other hand, sug-
gested that because primary channelopathies are
associated with myocardial structural abnormalities
such as DCM, this also occurs with HCN4. Their
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770second hypothesis was that LVNC is an acquired
adaptive remodeling feature in response to sinus
bradycardia.
One feature of the ﬁnal common pathway hy-
pothesis that may be at play here is the concept of
secondary disruption of the pathway via binding
partner abnormalities or other secondary causes.
Examples exist where a mutation in a non–ion
channel-encoding gene, such as caveolin-3 (Cav3) or
a-syntrophin 1 (SNTA1), disturbs the function of an
ion channel binding partner protein such as the
cardiac sodium channel gene, SCN5A, resulting
in an SCN5A form of long QT syndrome (LQT3)
(12,13). We termed these non-ion channel proteins
as ChIPs or channel interacting proteins. Many
similar examples exist. Using this example, we
could hypothesize that HCN4 mutations cause the
arrhythmia phenotype and also disturb downstream
binding partners that cause LVNC (sarcomere,
Z-disk, cytoskeletal proteins, or signaling path-
ways). There is a relative paucity of information
regarding HCN4 binding partners, but they include
Cav3, MiRP1 (encoded by the gene KCNE2 and
shown to be an auxiliary subunit of the HERG
channel), KCR1 (plasma membrane-associated pro-
tein that associates with HERG), SAP97 (membrane-
associated guanylate kinase scaffold protein), and
cyclic AMP. Several of these binding partners are
interesting as potential channel interacting protein-
like proteins. For instance, mutated Cav3 disrupts
SCN5A function causing LQT3 and arrhythmias (12).
In some patients with SCN5A disruption, an
arrhythmogenic DCM phenotype develops. Cav3,
SNTA1, and SCN5A also bind to dystrophin, the
protein that causes Duchenne and Becker muscular
dystrophy with DCM or LVNC, as does SAP97 (4,14).
Could a mutation in HCN4 disrupt the binding of
Cav3, SNTA1, or SAP97 and dystrophin, and be the
cause of LVNC in these patients? Another possibilityis disturbance of signaling pathways leading to an
overlapping phenotype. Notch signaling promotes
expression of conduction system-speciﬁc genes in
neonatal cardiomyocytes, reprogramming them into
cells with conduction system characteristics (15).
Human and animal studies suggest the Notch
pathway is involved in the development of LVNC
with or without CHD. Kuratomi et al. (16) demon-
strated that HCN4 enhancer function is depen-
dent on myocyte enhancer factor-2 (MEF2) binding
sequences, located in the regulatory region of
HCN4. Overexpression of a dominant-negative
MEF2 mutant inhibits enhancer activity, decreases
HCN4 mRNA expression, and decreases If current
amplitude, suggesting MEF2 may play a critical role
in HCN4 transcription. MEF2 signaling pathway
molecules interact with Notch pathway molecules,
including Hey2 and Tbx20, which are important in
the development of the myocardial compact and
noncompact layers, and are directly affected in
some forms of LVNC (17). It is possible that the
relationship of mutant HCN4 and MEF2 triggers a
downstream spiral that disturbs Notch pathway
function and results in LVNC with or without MVP,
whereas bradycardia occurs as a result of the pri-
mary HCN4 mutation.
In any case, these ﬁndings are intriguing and
potentially paradigm-shifting. If the investigators or
others can determine the pathogenic mechanism(s)
responsible for this overlapping phenotype, it would
enhance our knowledge and enable targeted treat-
ment development, especially because LVNC is
commonly associated with arrhythmias (18).
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